Physician profile
Robert Johnson
NPI 1790796654
$4,135.96
in general payments reported to CMS, 2019-2025
32 companies · $916 in 2025
The $916 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $409 · 2021: $446 · 2022: $382 · 2023: $653 · 2024: $989 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,212.56 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $668.06 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $365.63 | 2019-2023 | |
| Lilly USA, LLC | $320.97 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $221.61 | 2019-2025 | Repatha, Repatha, Otezla |
| Esperion Therapeutics, INC. | $120.20 | 2020-2025 | Nexletol |
| Abbvie INC. | $112.68 | 2021-2025 | |
| Pfizer INC. | $107.45 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $105.62 | 2023-2025 | Voquezna |
| Glaxosmithkline, LLC. | $99.91 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.63 | 2019-2025 | Jardiance, Synjardy |
| Supernus Pharmaceuticals, INC. | $82.33 | 2019-2020 | |
| Astellas Pharma US INC | $80.84 | 2024-2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $65.53 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $48.14 | 2020-2025 | Capvaxive, Gardasil 9 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $39.55 | 2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $38.66 | 2020-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $35.69 | 2019-2020 | |
| Genentech USA, INC. | $31.05 | 2019-2020 | |
| Eisai INC. | $29.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.60 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.36 | 2021 | |
| Amarin Pharma, INC. | $26.29 | 2020-2021 | |
| Mdd US Operations, LLC | $26.01 | 2022-2024 | Gocovri |
| Sanofi Pasteur INC. | $22.76 | 2019 | |
| Axsome Therapeutics, INC. | $22.44 | 2023 | Auvelity |
| Viatris Specialty LLC | $21.06 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $20.82 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $19.89 | 2025 | |
| Sunovion Pharmaceuticals INC. | $18.21 | 2022 | |
| Avion Pharmaceuticals | $12.10 | 2020 | |
| Inogen, INC. | $8.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.